Clinical study with cladribine completed

We have succesfully completed phase I study for female patients suffering from relapsing multiple sclerosis.

The aim of the study was to examine the effect of cladribine used in the treatment of relapsing multiple sclerosis on an oral contraceptive containing ethinyl estradiol and levonorgestrel.

Cladribine is a synthetic purine nucleoside that acts as an antineoplastic agent with immunosuppressive effects. Cladribine differs structurally from deoxyadenosine only by the presence of a chlorine atom at position 2 of the purine ring, which results in resistance to enzymatic degradation by adenosine deaminase.

Go back

News

Merry Christmas and Happy New Year

Let the magical night of Christmas Eve bring peace and joy. Let every moment of Christmas live with its own beauty, and bestows the New Year with prosperity and happiness.

Read more …

COVID -19 Antigen Tests:

On 31st of October 2020, the Chief Sanitary Inspectorate confirmed that the antigen cassette tests are the same basis for determining the SARS-CoV-2 ...

Read more …

BRG team participated in BIO-Europe®

On 26th -27th  of October BRG team participated in BIO-Europe® the largest partnering conference in Europe dedicated to the global biotechnology industry. 

Read more …

BRG Team participated in the official opening of the Celon Pharma Research and Development Center

On September 28, 2020 BRG Team participated in the official opening of the Celon Pharma Research and Development Center

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲